Combination therapy is almost the standard for treating chronic diseases, including chronic obstructive pulmonary disease (COPD). Until 2016, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendation for highly symptomatic COPD patients at risk of exacerbations or severe airflow limitation (GOLD D) was treatment with either long-acting muscarinic antagonists (LAMA) or long-acting β2-agonists (LABA) in combination with inhaled glucocorticosteroids (ICS), both with strong evidence. Triple therapy with LAMA/LABA/ICS was also recommended, but with panel consensus judgment, that is, based upon expert opinion only. To our knowledge, no properly powered and sufficiently long randomised clinical trial has ever shown that triple therapy is superior to LAMA, LABA/LAMA, or LABA/ ICS in reducing exacerbations as the primary outcome. However, one short study assessing lung function showed a significant reduction in exacerbations by triple therapy compared with LABA/ICS at 3 months.
Triple therapy for symptomatic patients with COPD / Fabbri, Lm; Roversi, S; Beghé, B.. - In: THE LANCET. - ISSN 0099-5355. - 389:10082(2017), pp. 1864-1865. [10.1016/S0140-6736(17)30567-6]
Triple therapy for symptomatic patients with COPD
Beghé B.
2017
Abstract
Combination therapy is almost the standard for treating chronic diseases, including chronic obstructive pulmonary disease (COPD). Until 2016, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendation for highly symptomatic COPD patients at risk of exacerbations or severe airflow limitation (GOLD D) was treatment with either long-acting muscarinic antagonists (LAMA) or long-acting β2-agonists (LABA) in combination with inhaled glucocorticosteroids (ICS), both with strong evidence. Triple therapy with LAMA/LABA/ICS was also recommended, but with panel consensus judgment, that is, based upon expert opinion only. To our knowledge, no properly powered and sufficiently long randomised clinical trial has ever shown that triple therapy is superior to LAMA, LABA/LAMA, or LABA/ ICS in reducing exacerbations as the primary outcome. However, one short study assessing lung function showed a significant reduction in exacerbations by triple therapy compared with LABA/ICS at 3 months.File | Dimensione | Formato | |
---|---|---|---|
fabbri2017.pdf
Accesso riservato
Tipologia:
Versione pubblicata dall'editore
Dimensione
290.54 kB
Formato
Adobe PDF
|
290.54 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris